Synopsis: Pharma shares rose 10% upon signing an agreement with GMBU e.V., Halle (Saale), Germany, on 2 June 2026 for commercial-scale production of Astaxanthin at its Hyderabad R&D facilities. The pact follows successful pilot production and aims to scale manufacturing.
The shares of a Penny stock company specialising in healthcare research, analytics, and the manufacturing, distribution, and trading of Active Pharmaceutical Ingredients (APIs), bulk drugs, and clinical formulations, are in focus as they have rallied 10 percent in the day’s trade.
With a market capitalization of Rs. 124.17 crores in the day’s trade, the shares of Novelix Pharmaceuticals Ltd rose by 10.3 percent, reaching a high of Rs. 60.00 per share compared to its previous closing price of Rs. 54.36 per share.
What Happened
Novelix Pharmaceuticals Ltd, engaged in healthcare research, analytics, and the manufacturing, distribution, and trading of Active Pharmaceutical Ingredients (APIs), bulk drugs, and clinical formulations, has informed the stock exchanges that it has entered into an agreement with GMBU e.V., Halle (Saale), Germany, on 2 June 2026.
The agreement is for the commercial-scale production of Astaxanthin at its research facilities in Hyderabad, India. The agreement follows the successful completion of pilot-scale production and is aimed at scaling up manufacturing capabilities for the product.
Financials & Others
The company’s revenue rose by 20.76 percent from Rs. 20.86 crores in March 2025 to Rs. 25.19 crores in March 2026. Meanwhile, Net profit rose from Rs. 0.18 crores to Rs. 0.91 crores in the same period.
The company shows moderate efficiency with ROCE of 9.98% and ROE of 8%, indicating stable but not high returns on capital and equity. A very low debt-to-equity ratio of 0.09 reflects a conservative, low-risk balance sheet with minimal leverage, suggesting growth is primarily funded through internal accruals rather than borrowed capital.
It has demonstrated strong long-term growth, with median sales growth of 42.1% over the past decade, showing consistent expansion. Working capital efficiency has improved significantly, with the cycle reducing from 222 days to 122 days, indicating better cash flow management. A PEG ratio of 0.22 suggests the stock may be undervalued relative to its growth.
The company has delivered very strong revenue expansion, with compounded sales growth of 152% over 5 years and an even sharper 310% over the last 3 years. This indicates rapid operational scaling and strong demand for its products or services, especially in the more recent period.
Novelix Pharmaceuticals Ltd is an Indian pharmaceutical company incorporated in 1994 and based in Hyderabad, Telangana. It is listed on the Bombay Stock Exchange and operates mainly in the pharmaceutical trading and related business. Over time, the company has also been involved in retailing pharmaceuticals, marketing services, and trading of shares and securities.
In recent years, the company has shifted its focus toward pharmaceutical research and development, especially in bulk drugs (Active Pharmaceutical Ingredients), intermediates, and healthcare-related analytics and technology services. It is a relatively small-cap firm with limited employees and is undergoing business expansion in the life sciences and pharma intermediates segment.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
